First Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, ...
Jupiter Neurosciences, Inc. announced that the first patient has been dosed in the company?s Phase 2a RESET clinical trial evaluating JOTROL? in patients with Parkinson?s disease . The dosing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results